keyword
https://read.qxmd.com/read/32754748/cost-effectiveness-and-efficacy-of-a-novel-combination-regimen-in-acromegaly-a-prospective-randomized-trial
#1
Vivien Bonert, James Mirocha, John Carmichael, Kevin C J Yuen, Takako Araki, Shlomo Melmed
CONTEXT: Combination therapy with somatostatin receptor ligand (SRL) plus pegvisomant for acromegaly patients is recommended after maximizing dose on monotherapy. Lower-dose combination regimens are not well-studied. OBJECTIVE: To compare cost-effectiveness and efficacy of three lower-dose combination regimens in controlled and uncontrolled acromegaly. DESIGN AND SETTING: Prospective, randomized, open-label, parallel arm study at a tertiary referral pituitary center...
July 10, 2020: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/32748523/octreotide-and-lanreotide-decrease-ovarian-ischemia-reperfusion-injury-in-rats-by-improving-oxidative-and-nitrosative-stress
#2
Senol Kalyoncu, Bulent Yilmaz, Mustafa Demir, Meltem Tuncer, Zehra Bozdag, Onur Ince, Mehmet Akif Bozdayi, Hasan Ulusal, Seyithan Taysi
AIM: To investigate the protective effect of octreotide and lanreotide on ovarian damage in experimental ovarian ischemia-reperfusion injury. METHODS: Fifty-six rats were separated into seven groups; group 1: sham group, group 2: surgical control group with 3-h torsion and detorsion, group 3: 0.02 mg/kg s.c. octreotide 30 min before 3-h torsion, group 4; octreotide just after detorsion for 7 days, group 5: octreotide 30 min before torsion and just after detorsion for 7 days, group 6: single time 20 mg/kg s...
August 3, 2020: Journal of Obstetrics and Gynaecology Research
https://read.qxmd.com/read/32746647/is-lanreotide-really-useful-in-high-output-stoma-comparison-between-lanreotide-to-conventional-antidiarrheal-treatment-alone
#3
Yannis Mesli, Lise Holterbach, Jean-Baptiste Delhorme, Zaher Lakkis, Pablo Ortega-Deballon, Sophie Deguelte, Serge Rohr, Cécile Brigand, Nicolas Meyer, Benoit Romain
BACKGROUND: The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment. METHODS: Patients with an ileostomy output ≥ 1.5 l/24 hours were included in this prospective, open, multicentre randomized trial...
August 4, 2020: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
https://read.qxmd.com/read/32725444/effectiveness-of-lanreotide-autogel-120-mg-at-extended-dosing-intervals-for-acromegaly
#4
Ignacio Bernabéu, Carmen Fajardo, Mónica Marazuela, Fernando Cordido, Eva María Venegas, Pedro de Pablos-Velasco, Gonzalo Piedrola Maroto, María Pilar Olvera, Isabel Pavón de Paz, Davide Carvalho, Carme Romero, Guillermo De la Cruz, Cristina Álvarez Escolá
PURPOSE: Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. METHODS: Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233)...
July 28, 2020: Endocrine
https://read.qxmd.com/read/32617128/incidental-primary-breast-cancer-detected-on-surveillance-68-ga-dotatate-pet-ct-in-a-patient-with-metastatic-neuroendocrine-carcinoma
#5
Emily B Ambinder, Rudolf A Werner, Steven P Rowe
We present a case of a 53-year-old woman with metastatic neuroendocrine tumor, presumed primary in the small intestine with metastases to the liver and mesenteric lymph nodes. The patient was being treated with lanreotide and followed with somatostatin receptor (SSTR)-targeted 68Ga-labeled 1,4,7,10-tetraazacyclododecane- N,N ', N '', N '''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotate (68 Ga-DOTATATE) positron emission tomography - computed tomography (PET/CT). On a follow-up exam, the patient's primary and metastatic disease had improved but she had new 68 Ga-DOTATATE-avid lesions in the right breast and right axilla...
August 2020: Radiology Case Reports
https://read.qxmd.com/read/32604431/medical-therapy-of-acromegaly-in-germany-2019-data-from-the-german-acromegaly-registry
#6
Marcus Quinkler, David Petroff, Ulrich J Knappe, Jochen Schopohl, Anke Tönjes, Sebastian M Schmid
CONTEXT: Acromegaly is a rare disease caused by excessive growth hormone (GH) secretion from pituitary adenomas in most cases. If neurosurgical therapy is contraindicated or not sufficient, medical therapy is the second line therapy. OBJECTIVE: To describe current medical therapy in acromegaly. DESIGN & METHODS: Retrospective data analysis from 2732 patients treated in 69 centers of the German Acromegaly Registry. 749 patients were seen within the recent 18 months, of which 420 were on medical therapy (56...
June 30, 2020: Experimental and Clinical Endocrinology & Diabetes
https://read.qxmd.com/read/32590392/somatostatin-analogs-in-pregnant-patients-with-neuroendocrine-tumor
#7
Giulia Meoni, Elisa Giommoni, Paolo Petreni, Serena Pillozzi, Francesca Mazzoni, Elisa Pellegrini, Marco Brugia, Alice Lunghi, Andrea Muto, Lorenzo Antonuzzo
Somatostatine analogs (SSAs) are currently indicated in the treatment of acromegaly and neuroendocrine tumors (NETs). Actually, pregnancy in patients with acromegaly and NETs does not represent an exceptional event because reproductive behavior has changed in the last decades and patients with NETs show more frequently long-term survival. The safety profile of SSAs during pregnancy is still controversial. Concerning acromegaly, based on case reports and series, SSAs administration during pregnancy seems to be relatively well tolerated...
June 23, 2020: Anti-cancer Drugs
https://read.qxmd.com/read/32542576/tumour-to-liver-ratio-determined-by-68-ga-ga-dota-toc-pet-ct-as-a-prognostic-factor-of-lanreotide-efficacy-for-patients-with-well-differentiated-gastroenteropancreatic-neuroendocrine-tumours
#8
Yong-Il Kim, Changhoon Yoo, Seung Jun Oh, Sang Ju Lee, Junho Kang, Hee-Sang Hwang, Seung-Mo Hong, Baek-Yeol Ryoo, Jin-Sook Ryu
BACKGROUND: Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally established prognostic factors associated with the efficacy of lanreotide as a treatment for GEP-NETs. We investigated the prognostic value of [68 Ga]Ga-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) somatostatin receptor imaging for patients with WD GEP-NETs treated with lanreotide...
June 15, 2020: EJNMMI Research
https://read.qxmd.com/read/32541155/antiproliferative-effect-of-above-label-doses-of-somatostatin-analogs-for-the-management-of-gastroenteropancreatic-neuroendocrine-tumors
#9
Leonidas Diamantopoulos, Faidon-Marios Laskaratos, Markos Kalligeros, Ruchir Shah, Shaunak Navalkissoor, Gopinath Gnanasegaran, Jamie Banks, Jack Smith, Benjamin Jacobs, Michail Galanopoulos, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
INTRODUCTION: Above-label doses of somatostatin analogs (SSAs) are increasingly utilized in the management of inoperable/metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), progressing on standard 4-weekly regimens. OBJECTIVE: To evaluate the antiproliferative effect of 3-weekly SSA administration in a retrospective GEP-NETs cohort. METHODS: Patients with advanced GEP-NETs, treated with long acting release (LAR) octreotide 30mg or lanreotide Autogel 120mg at a 3-weekly interval, after disease progression on standard 4-weekly doses, were retrospectively identified...
June 15, 2020: Neuroendocrinology
https://read.qxmd.com/read/32440136/octreotide-resistant-acromegaly-challenges-and-solutions
#10
REVIEW
Giuliana Corica, Marco Ceraudo, Claudia Campana, Federica Nista, Francesco Cocchiara, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Diego Ferone, Federico Gatto
Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life expectancy. Current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment...
2020: Therapeutics and Clinical Risk Management
https://read.qxmd.com/read/32375590/preoperative-treatment-of-benign-insulinoma-diazoxide-or-somatostatin-analogues
#11
Quentin Gilliaux, Claude Bertrand, François Hanon, Julian E Donckier
Surgery is the ideal treatment of insulinoma. However, systemic therapy may be required to prevent severe preoperative hypoglycaemia, when surgery is contraindicated, delayed or refused and in case of unresectable metastatic disease. Diazoxide is commonly used but is not always effective and can cause serious side effects. Somatostatin analogues (octreotide and lanreotide) may be an alternative option. We report the case of a 27-year-old patient with insulinoma in whom diazoxide was compared with lanreotide before operation...
May 18, 2020: Acta Chirurgica Belgica
https://read.qxmd.com/read/32366244/efficacy-and-safety-of-lanreotide-autogel-compared-with-lanreotide-40-mg-prolonged-release-in-chinese-patients-with-active-acromegaly-results-from-a-phase-3-prospective-randomized-and-open-label-study-lantern
#12
Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu
BACKGROUND: Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release (PR) in Chinese patients with active acromegaly. METHODS: LANTERN was a phase 3, randomized, open-label, non-inferiority study. Patients with active acromegaly who had undergone surgery ≥3 months prior, or were unlikely or unable to undergo surgery, were treated with lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection) or lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days) for 32 weeks...
May 4, 2020: BMC Endocrine Disorders
https://read.qxmd.com/read/32338854/response-of-thyrotropin-secreting-pituitary-tumors-to-preoperative-lanreotide-therapy-report-of-two-cases
#13
Akemi Tokutsu, Yosuke Okada, Keiichi Torimoto, Takashi Otsuka, Manabu Narisawa, Akira Kurozumi, Yoshiya Tanaka
Case 1 was a 51-year-old man diagnosed with thyrotropin (TSH)-secreting pituitary tumor. The octreotide loading test showed suppression of TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. Three months after treatment initiation, tumor shrinkage was observed, and pituitary tumor resection was performed through transsphenoidal surgery. Case 2 was a 47-year-old woman in whom the octreotide loading test showed suppressed TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function...
April 27, 2020: Neuro Endocrinology Letters
https://read.qxmd.com/read/32299084/pharmacological-acromegaly-treatment-cost-utility-and-value-of-information-analysis
#14
Leticia P Leonart, Bruno S Riveros, Murray D Krahn, Roberto Pontarolo
OBJECTIVES: To conduct a cost-utility analysis comparing drug strategies involving octreotide, lanreotide, pasireotide, and pegvisomant for the treatment of patients with acromegaly who have failed surgery, from a Brazilian public payer perspective. METHODS: A probabilistic cohort Markov model was developed. One-year cycles were employed. The patients started at 45 years of age and were followed lifelong. Costs, efficacy, and quality of life parameters were retrieved from the literature...
April 16, 2020: Neuroendocrinology
https://read.qxmd.com/read/32217809/pasireotide-for-acromegaly-long-term-outcomes-from-an-extension-to-the-phase-iii-paola-study
#15
Annamaria Anita Livia Colao, M D Bronstein, Thierry Brue, Laura De Marinis, Maria Fleseriu, Mirtha Guitelman, Gerald Raverot, Ilan Shimon, Jürgen Fleck, Pritam Gupta, Alberto M Pedroncelli, Monica R Gadelha
OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with octreotide/lanreotide (active control) at month 6. The current work assessed the extent of comorbidities at baseline and outcomes during a long-term extension. DESIGN/METHODS: Patients receiving pasireotide 40 or 60 mg at core study end could continue on the same dose in an extension phase if biochemically controlled, or receive pasireotide 60 mg if uncontrolled...
March 1, 2020: European Journal of Endocrinology
https://read.qxmd.com/read/32213066/response-and-relapse-rates-after-treatment-with-long-acting-somatostatin-analogs-in-multifocal-or-recurrent-type-1-gastric-carcinoids-a-systematic-review-and-meta-analysis
#16
Roberta Elisa Rossi, Pietro Invernizzi, Vincenzo Mazzaferro, Sara Massironi
BACKGROUND: Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear. We performed a systematic review of the literature to clarify the role of somatostatin analog treatment in type-1 gastric neuroendocrine tumors. METHODS: A computerized literature search was performed using relevant keywords to identify all the pertinent articles published in the last 15 years...
March 2020: United European Gastroenterology Journal
https://read.qxmd.com/read/32168252/metastatic-vipoma-cosecreting-insulin-with-complete-response-to-lanreotide-capecitabine-and-temozolomide
#17
Bernardo Marques, Ana Raquel Monteiro, Raquel G Martins, Joana Couto, Fernando Rodrigues, João Ribeiro
No abstract text is available yet for this article.
March 2020: Pancreas
https://read.qxmd.com/read/32157626/evaluation-of-nurse-preferences-between-the-lanreotide-autogel-new-syringe-and-the-octreotide-long-acting-release-syringe-an-international-simulated-use-study-presto
#18
Daphne Adelman, Xuan-Mai Truong Thanh, Marion Feuilly, Aude Houchard, David Cella
INTRODUCTION: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe...
March 11, 2020: Advances in Therapy
https://read.qxmd.com/read/32126984/p-l105vfs-mutation-in-a-family-with-thymic-neuroendocrine-tumor-combined-with-men1-a-case-report
#19
Hongjuan Zheng, Shishi Zhou, Wanfen Tang, Qinghua Wang, Xia Zhang, Xiayun Jin, Ying Yuan, Jianfei Fu
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder arising from mutations of the MEN1 tumor suppressor gene on chromosome 11q13; MEN1 is characterized by the development of neuroendocrine tumors, including those of the parathyroid, gastrointestinal endocrine tissue and anterior pituitary. Additionally, thymic neuroendocrine tumors in MEN1 are also rarely reported. CASE PRESENTATION: This case report observed a family that presented with MEN1 p...
March 4, 2020: BMC Neurology
https://read.qxmd.com/read/32062681/lessons-from-a-multicentre-retrospective-study-of-peptide-receptor-radionuclide-therapy-combined-with-lanreotide-for-neuroendocrine-tumours-a-need-for-standardised-practice
#20
Vikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, Chiara Maria Grana, Sergio Baldari, Tahir Shah, Angela Lamarca, Frédéric Courbon, Klemens Scheidhauer, Eric Baudin, Xuan-Mai Truong Thanh, Aude Houchard, Clarisse Dromain, Lisa Bodei
PURPOSE: PRELUDE aimed to assess use and effectiveness/safety of lanreotide autogel/depot (LAN) combined with 177 Lu-DOTATOC or 177 Lu-DOTATATE (LAN-peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs). METHODS: International, non-interventional, retrospective, non-comparative analysis of medical records from patients with progressive metastatic or locally advanced grade 1 or 2 gastroenteropancreatic (GEP)- or lung-NETs...
February 15, 2020: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
81166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"